Tech Company Financing Transactions
PAQ Therapeutics Funding Round
PAQ Therapeutics closed a Series B financing round on 1/26/2026. Investors included private investors.
Transaction Overview
Company Name
Announced On
1/26/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the ongoing Phase 1 development of PT0253, its KRAS G12D degrader, as well as the clinical advancement of PT0511.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
625 Mass Ave. 02-146
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
PAQ's platform is driven by autophagosome-tethering compounds (ATTECs), small molecules with the potential to catalyze and selectively enhance the degradation of disease-causing entities through autophagy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nan Ji
Co-Founder
Huaixiang Hao
Browse more venture capital transactions:
Prev: 1/26/2026: Tradespace venture capital transaction
Next: 1/26/2026: Grove venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs